1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

Material: Sertraline Tablets USP
25 mg, 50 mg and 100 mg

Manufacturer: Lupin Limited
Goa 403 722
INDIA.

Distributor: Lupin Pharmaceuticals, Inc.
Harborplace Tower, 21st Floor
111, South Calvert Street
Baltimore, MD 21202
United States
Tel. 001-410-576-2000
Fax 001-410-576-2221

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients | CAS | Quantity
--- | --- | ---
Sertraline Hydrochloride USP | 79559-97-0 | 25 mg, 50 mg and 100 mg

3. HAZARDOUS IDENTIFICATION

Fire and Explosion
Assume that this product is capable of sustaining combustion.

Health
The use of MAOIs intended to treat psychiatric disorders with sertraline or within 14 days of stopping treatment with sertraline is contraindicated because of an increased risk of serotonin syndrome. The use of sertraline within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated.

Starting sertraline in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome.

Concomitant use in patients taking pimozide is contraindicated.

Sertraline tablets are contraindicated in patients with a hypersensitivity to sertraline or any of the inactive ingredients in sertraline tablets.

Environment
No information is available about the potential of this product to produce adverse environmental effects.
4. FIRST AID MEASURES

Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact
Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Human Experience
Of 1,027 cases of overdose involving sertraline hydrochloride worldwide, alone or with other drugs, there were 72 deaths (circa 1999).

Among 634 overdoses in which sertraline hydrochloride was the only drug ingested, 8 resulted in fatal outcome, 75 completely recovered, and 27 patients experienced sequelae after overdosage to include alopecia, decreased libido, diarrhea, ejaculation disorder, fatigue, insomnia, somnolence and serotonin syndrome. The remaining 524 cases had an unknown outcome. The most common signs and symptoms associated with non-fatal sertraline hydrochloride overdosage were somnolence, vomiting, tachycardia, nausea, dizziness, agitation and tremor.

The largest known ingestion was 13.5 grams in a patient who took sertraline hydrochloride alone and subsequently recovered. However, another patient who took 2.5 grams of sertraline hydrochloride alone experienced a fatal outcome.

Other important adverse events reported with sertraline hydrochloride overdose (single or multiple drugs) include bradycardia, bundle branch block, coma, convulsions, delirium, hallucinations, hypertension, hypotension, manic reaction, pancreatitis, QT-interval prolongation, serotonin syndrome, stupor and syncope.

Overdose Management
Treatment should consist of those general measures employed in the management of overdosage with any antidepressant.

Ensure an adequate airway, oxygenation and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with
appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients.

Activated charcoal should be administered. Due to large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for sertraline are known.

In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the *Physicians' Desk Reference®* (PDR®).

### 5. FIRE-FIGHTING MEASURES

- **Fire and Explosion Hazards**: Assume that this product is capable of sustaining combustion.
- **Extinguishing Media**: Water spray, carbon dioxide, dry chemical powder or appropriate foam.
- **Special Firefighting Procedures**: For single units (packages): No special requirements needed.
- **Hazardous Combustion Products**: Hazardous combustion or decomposition products are expected when the product is exposed to fire.

### 6. ACCIDENTAL RELEASE MEASURES

- **Personal Precautions**: Wear protective clothing and equipment consistent with the degree of hazard.
- **Environmental Precautions**: For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
- **Clean-up Methods**: Collect and place it in a suitable, properly labeled container for recovery or disposal.

### 7. HANDLING AND STORAGE

- **Handling**: No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
- **Storage**: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

9. PHYSICAL & CHEMICAL PROPERTIES

Physical Form

Sertraline capsule-shaped, film-coated tablets, containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline, are packaged in bottles as well as unit dose blisters.

Sertraline Tablets USP, 25 mg: green colored, capsule shaped, biconvex, film-coated tablets, debossed with 'L' & 'U' on either side of the breakline on one side and 'D01' on the other side.

- NDC 68180-351-06 Bottles of 30
- NDC 68180-351-08 Bottles of 50
- NDC 68180-351-09 Bottles of 90
- NDC 68180-351-01 Bottles of 100
- NDC 68180-351-03 Bottles of 1000

Sertraline Tablets USP, 50 mg: blue colored, capsule shaped, biconvex, film-coated tablets, debossed with ‘L’ & ‘U’ on either side of the breakline on one side and ‘D02’ on the other side.

- NDC 68180-352-06 Bottles of 30
- NDC 68180-352-09 Bottles of 50
- NDC 68180-352-01 Bottles of 100
- NDC 68180-352-02 Bottles of 500
- NDC 68180-352-03 Bottles of 1000
- NDC 68180-352-05 Bottles of 5000
- NDC 68180-352-11 Box containing 10 x 10’s unit dose blisters

Sertraline Tablets USP, 100 mg: yellow colored, capsule shaped, biconvex, film-coated tablets, debossed with 'L' & 'U' on either side of the breakline on one side and 'D03' on the other side.

- NDC 68180-353-06 Bottles of 30
- NDC 68180-353-09 Bottles of 50
- NDC 68180-353-01 Bottles of 100
- NDC 68180-353-02 Bottles of 500
- NDC 68180-353-03 Bottles of 1000
- NDC 68180-353-05 Bottles of 5000
- NDC 68180-353-11 Box containing 10 x 10’s unit dose blisters
10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

11. TOXICOLOGICAL INFORMATION

Carcinogenesis

Lifetime carcinogenicity studies were carried out in CD-1 mice and Long-Evans rats at doses up to 40 mg/kg/day. These doses correspond to 1 times (mice) and 2 times (rats) the maximum recommended human dose (MRHD) on a mg/m² basis. There was a dose-related increase of liver adenomas in male mice receiving sertraline at 10 to 40 mg/kg (0.25 to 1.0 times the MRHD on a mg/m² basis). No increase was seen in female mice or in rats of either sex receiving the same treatments, nor was there an increase in hepatocellular carcinomas. Liver adenomas have a variable rate of spontaneous occurrence in the CD-1 mouse and are of unknown significance to humans. There was an increase in follicular adenomas of the thyroid in female rats receiving sertraline at 40 mg/kg (2 times the MRHD on a mg/m² basis); this was not accompanied by thyroid hyperplasia. While there was an increase in uterine adenocarcinomas in rats receiving sertraline at 10 to 40 mg/kg (0.5 to 2.0 times the MRHD on a mg/m² basis) compared to placebo controls, this effect was not clearly drug related.

Mutagenesis

Sertraline had no genotoxic effects, with or without metabolic activation, based on the following assays: bacterial mutation assay; mouse lymphoma mutation assay; and tests for cytogenetic aberrations in vivo in mouse bone marrow and in vitro in human lymphocytes.

Impairment of Fertility

A decrease in fertility was seen in one of two rat studies at a dose of 80 mg/kg (4 times the maximum recommended human dose on a mg/m² basis).

12. ECOLOGICAL INFORMATION

No relevant studies identified.

13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.
14. TRANSPORT INFORMATION

IATA/ICAO - Not Regulated
IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated
IMDG Proper shipping Name : N/A
IMDG UN/ID No : N/A
IMDG Hazard Class : N/A
IMDG Flash Point : N/A
IMDG Label : N/A

DOT - Not Regulated
DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

15. REGULATORY INFORMATION

This Section Contains Information relevant to compliance with other Federal and/or state laws.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.